Episode 90: The MS Association of America with President & CEO Gina Murdoch

Episode 90: The MS Association of America with President & CEO Gina Murdoch

Publication date: May 20, 2019

The Multiple Sclerosis Association of America, or MSAA, provides programs and resources designed to improve the lives of people affected by MS. Whether it’s financial assistance for an MRI exam, a new computer, mobility equipment, or even a cooling vest, the MSAA can help. My guest today is Gina Murdoch, the President and CEO of the MSAA, and we’re talking about the organization’s almost 50-year history, their shared management philosophy of living with MS, and we’re taking a deeper dive into into some of their remarkable programs. We’re also talking about the Progressive MS Alliance Scientific Steering Committee Meeting that begins tomorrow in Copenhagen, Denmark. You’ll hear about the Patient 360 meeting that EMD Serono hosted last week in Washington, D.C., and I’ll tell you why that meeting was so special to me. We’re talking about the just announced $100,000 research grant to investigate the challenges faced by people of color who are living with MS and their caregivers. You’ll learn about the special search engine that matches MS patients with financial support for disease-modifying therapy. We’ll tell you about 2 new programs from Can-Do MS, focused on young adults who are living with MS and people who are living with secondary progressive MS. And you’ll find out how you can be my special guest on the 100th episode of RealTalk MS. We have a lot to talk about. Are you ready for RealTalk MS??! Progressive MS Alliance Scientific Steering Committee Meeting in Copenhagen :22 EMD Serono Hosts Patient 360 Meeting 2:27 Accelerated Cure Project & Us Against Alzheimer’s Receive $100,000 Grant to Study Challenges Faced by People of Color Living with MS & Alzheimer’s Disease 6:07 MAT Can Connect You to Financial Support for Disease-Modifying Therapy 7:53 Can-Do MS Announces Programs for Young Adults Living with MS and People Living with Secondary Progressive MS 9:58 Finalists Announced for Lyfebulb-Celgene Addressing Unmet Needs in MS: Innovation Challenge 12:22 My Interview with MSAA’s Gina Murdoch 16:13 ___________ ADD YOUR VOICE TO THE CONVERSATION I’ve always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.comPhone: (310) 526-2283 ___________ LINKS If your podcast app doesn’t allow you to click on these links, you’ll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com International Progressive MS Alliance Multiple Sclerosis Association of America MAT (Medicine Assistance Tool) Can-Do MS Young Adults Take Charge Program Can-Do MS Secondary Progressive MS Webinar Series Celgene Lyfebulb MS Innovation Challenge Be My Guest on RealTalk MS Episode #100 Download the RealTalk MS App for iOS Download the RealTalk MS App for Android Give RealTalk MS a Rating & Review ___________ Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 90 Hosted By: Jon Strum Guest: Gina Murdoch Tags: MS, MultipleSclerosis, MSResearch, ProgressiveMS, CanDoMS, MSAA, EMDSerono, Celgene, Lyfebulb, Caregiving, RealTalkMS

Concepts Keywords
Alzheimer Search engine
Android Mobility equipment
Celgene Multiple sclerosis
CEO Search engine
Copenhagen Android
Denmark MRI
IOS
MRI
Multiple Sclerosis
Philosophy
Podcast
President
Progressive
Search Engine
Tool
Twitter
Washington

Semantics

Type Source Name
disease MESH Multiple Sclerosis
disease DOID Multiple Sclerosis
gene UNIPROT CYREN
drug DRUGBANK Nonoxynol-9
gene UNIPROT EMD
gene UNIPROT MAT1A
gene UNIPROT ACAT1
gene UNIPROT CHL1
gene UNIPROT APP
drug DRUGBANK Coenzyme M
drug DRUGBANK Methyltestosterone

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *